LY404039 - CAS 635318-11-5
Catalog number: 635318-11-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C7H9NO6S
Molecular Weight:
235.22
COA:
Inquire
Targets:
mGluR
Description:
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
GW786034 HCl
MSDS:
Inquire
1.Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Deutschenbaur L1, Beck J1, Kiyhankhadiv A1, Mühlhauser M1, Borgwardt S1, Walter M1, Hasler G1, Sollberger D1, Lang UE2. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:325-33. doi: 10.1016/j.pnpbp.2015.02.015. Epub 2015 Mar 4.
Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has been observed by ketamine, which acts via the glutamatergic system. Hence, a steady accumulation of evidence supporting a role for the excitatory amino acid neurotransmitter (EAA) glutamate in the treatment of depression has been observed in the last years. Emerging evidence indicates that N-methyl-D-aspartate (NMDA), group 1 metabotropic glutamate receptor antagonists and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) agonists have antidepressant properties. Indeed, treatment with NMDA receptor antagonists has shown the ability to sprout new synaptic connections and reverse stress-induced neuronal changes. Based on glutamatergic signaling, a number of therapeutic drugs might gain interest in the future. Several compounds such as ketamine, memantine, amantadine, tianeptine, pioglitazone, riluzole, lamotrigine, AZD6765, magnesium, zinc, guanosine, adenosine aniracetam, traxoprodil (CP-101,606), MK-0657, GLYX-13, NRX-1047, Ro25-6981, LY392098, LY341495, D-cycloserine, D-serine, dextromethorphan, sarcosine, scopolamine, pomaglumetad methionil, LY2140023, LY404039, MGS0039, MPEP, 1-aminocyclopropanecarboxylic acid, all of which target this system, have already been brought up, some of them recently.
2.Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.
Ahnaou A1, Biermans R1, Drinkenburg WH1. PLoS One. 2016 Jan 25;11(1):e0147365. doi: 10.1371/journal.pone.0147365. eCollection 2016.
Improvement of cognitive impairments represents a high medical need in the development of new antipsychotics. Aberrant EEG gamma oscillations and reductions in the P1/N1 complex peak amplitude of the auditory evoked potential (AEP) are neurophysiological biomarkers for schizophrenia that indicate disruption in sensory information processing. Inhibition of phosphodiesterase (i.e. PDE10A) and activation of metabotropic glutamate receptor (mGluR2) signaling are believed to provide antipsychotic efficacy in schizophrenia, but it is unclear whether this occurs with cognition-enhancing potential. The present study used the auditory paired click paradigm in passive awake Sprague Dawley rats to 1) model disruption of AEP waveforms and oscillations as observed in schizophrenia by peripheral administration of amphetamine and the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP); 2) confirm the potential of the antipsychotics risperidone and olanzapine to attenuate these disruptions; 3) evaluate the potential of mGluR2 agonist LY404039 and PDE10 inhibitor PQ-10 to improve AEP deficits in both the amphetamine and PCP models.
3.Hydrophilic interaction chromatography with aerosol-based detectors (ELSD, CAD, NQAD) for polar compounds lacking a UV chromophore in an intravenous formulation.
Cintrón JM1, Risley DS. J Pharm Biomed Anal. 2013 May 5;78-79:14-8. doi: 10.1016/j.jpba.2013.01.022. Epub 2013 Jan 26.
In this work, a high performance liquid chromatography (HPLC) method is reported for the separation and quantitation of a drug substance that is highly polar and lacking a chromophore in a mannitol intravenous (IV) formulation. Three polar stationary phases operated in hydrophilic interaction chromatography (HILIC) mode were evaluated in conjunction with an Alltech 800 ELSD detector. These columns were evaluated with respect to chromatographic properties such as buffer, pH and organic concentrations to identify the best stationary phase. The chromatographic method was then validated for the determination of mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-Amino-2-sulfonylbicyclo [3.1.0] hexane-4,6-dicarboxylic acid (LY404039) content in a mannitol IV formulation with respect to linearity (R(2) of 0.9997), repeatability (%RSD of 0.36%), accuracy, solution stability (99.56% after 24h), specificity, intra-assay precision (%RSD 0.48%) and limit of detection (LOD, ∼50 μg/mL).
4.In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.
Moulton RD1, Ruterbories KJ2, Bedwell DW2, Mohutsky MA2. Drug Metab Dispos. 2015 May;43(5):756-61. doi: 10.1124/dmd.114.062893. Epub 2015 Mar 9.
To characterize the hydrolysis of the peptide prodrug pomaglumetad methionil (LY2140023; (1R,4S,5S,6S)-4-(L-methionylamino)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide), to the active drug LY404039 [(1R,4S,5S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide], a series of in vitro studies were performed in various matrices, including human intestinal, liver, kidney homogenate, and human plasma. The studies were performed to determine the tissue(s) and enzyme(s) responsible for the conversion of the prodrug to the active molecule. This could enable an assessment of the risk for drug interactions, an evaluation of pharmacogenomic implications, as well as the development of a Physiologically Based Pharmacokinetic (PBPK) model for formation of the active drug. Of the matrices examined, hydrolysis of pomaglumetad methionil was observed in intestinal and kidney homogenate preparations and plasma, but not in liver homogenate.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products


CAS 191471-52-0 LY 379268

LY 379268
(CAS: 191471-52-0)

LY 379268 is a group II mGlu receptor agonist with EC50 values of 2.69 and 4.48 nM for hmGlu2 and hmGlu3. Some research shows that LY379268 can attenuate cocain...

CAS 852679-66-4 (±)-LY 395756

(±)-LY 395756
(CAS: 852679-66-4)

(±)-LY 395756 is a mixed mGlu2 agonist/mGlu3 antagonist.

CAS 433967-28-3 VU 0357121

VU 0357121
(CAS: 433967-28-3)

VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes.

CAS 338736-46-2 LY 456236 hydrochloride

LY 456236 hydrochloride
(CAS: 338736-46-2)

LY 456236 hydrochloride is a mGlu1 receptor antagonist with IC50 value of 143 nM. It may be used in the treatment of chronic pain.

CAS 885104-09-6 LY 2389575 hydrochloride

LY 2389575 hydrochloride
(CAS: 885104-09-6)

LY 2389575 hydrochloride is a mGluR3 receptor antagonist with IC50 value of 190 nM.

CAS 873551-53-2 FTIDC

FTIDC
(CAS: 873551-53-2)

FTIDC is an orally bioactive mGlu1 receptor negative allosteric modulator (IC50 = 5.8 and 6200 nM for mGlu1 and mGlu5, respectively) and an mGlu1 receptor inver...

CAS 6266-99-5 SIB 1893

SIB 1893
(CAS: 6266-99-5)

SIB 1893 is a selective and noncompetitive antagonist for the metabotropic glutamate mGlu5 receptor subtype (IC50 = 0.3 μM and > 100 μM at hmGlu5, hmGlu1b, hmGl...

CAS 170984-72-2 EGLU

EGLU
(CAS: 170984-72-2)

EGLU is a group II mGluR antagonist and also a selective antagonist of presynaptically-mediated (1S,3S)-ACPD-induced depression of motoneuron excitation in neon...

CAS 936095-50-0 ACET

ACET
(CAS: 936095-50-0)

ACET, a potent and selective GluR5-containing kainate receptor antagonist, has been found to exhibit activities in blocking induction of NMDA receptor-independe...

CAS 31932-87-3 (RS)-3-Hydroxyphenylglycine

(RS)-3-Hydroxyphenylglycine
(CAS: 31932-87-3)

(RS)-3-Hydroxyphenylglycine is an agonist at PI-linked metabotropic glutamate receptors.

CAS 31993-01-8 SIB 1757

SIB 1757
(CAS: 31993-01-8)

SIB 1757 is a highly selective antagonist for the metabotropic glutamate mGlu5 receptor subtype (IC50 = 0.4 μM and > 30 μM at hmGlu5, hmGlu1b, hmGlu2, hmGlu4, h...

CAS 226878-01-9 NPS 2390

NPS 2390
(CAS: 226878-01-9)

NPS 2390 is a Group I mGlu antagonist. NPS 2390 acts as a noncompetitive antagonist of mGluR1 and mGluR5 with IC50 values of 5.2 and 82 nM.

CAS 1093757-42-6 VU 0155041

VU 0155041
(CAS: 1093757-42-6)

VU 0155041 is a potent positive allosteric modulator at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors, respectively). VU 0155041 displ...

CAS 1224431-15-5 MFZ 10-7

MFZ 10-7
(CAS: 1224431-15-5)

MFZ 10-7 is a mGlu5 receptor negative allosteric modulator. It can inhibit mGlu5 glutamate-mediated calcium mobilization with IC50 value of 1.22 nM. MFZ 10-7 ca...

CAS 56-85-9 L-Glutamine

L-Glutamine
(CAS: 56-85-9)

L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.

CAS 1263273-14-8 (1R,2S)-VU0155041

(1R,2S)-VU0155041
(CAS: 1263273-14-8)

(1R,2S)-VU0155041 is a partial mGluR4-positive allosteric modulator (EC50= 2.35 μM) that dependently attenuated hyperalgesia in neuropathic pain model rats.

CAS 1445605-23-1 Lu AF21934

Lu AF21934
(CAS: 1445605-23-1)

Lu AF21934 is a selective and brain-penetrating positive allosteric modulator (PAM) of mGlu4 receptors (IC50= 500 nM) on the harmaline-induced tremor and other ...

CAS 446257-23-4 YM 230888

YM 230888
(CAS: 446257-23-4)

YM 230888 is a selective mGlu1 antagonist (Ki = 13 nM) that inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells (IC50 = 13 nM)...

CAS 1431980-60-7 TASP 0433864

TASP 0433864
(CAS: 1431980-60-7)

TASP 0433864 is a selective and positive allosteric modulator of mGlu2 receptor (EC50 = 199 and 206 nM for human and rat receptors, respectively) with no agonis...

CAS 55136-48-6 (S)-3-Carboxy-4-hydroxyphenylglycine

(S)-3-Carboxy-4-hydroxyphenylglycine
(CAS: 55136-48-6)

(S)-3-Carboxy-4-hydroxyphenylglycine has been found to be a mixed group II mGlu agonist as well as group I metabotropic glutamate receptor antagonist.

Chemical Structure

CAS 635318-11-5 LY404039

Quick Inquiry

Verification code

Featured Items